Renaissance Capital logo

TLCR News

Talecris Biotherapeutics quiet period ends November 9

Talecris Biotherapeutics, former Bayer maker of plasma-derived protein therapies LBO'd by Cerberus, will see its quiet period end on Nov. 9. On September 30, 2009, the company raised $950 million by offering 50 million shares at $19.00, within the expected...read more

Worst weekly performers: A123 Systems, Echo Global, Talecris Bio.

The following companies were the worst performing IPOs over the last five trading sessions:

...read more

Talecris Biotherapeutics prices IPO at $19.00 midpoint, increases deal size by 12%

Talecris Biotherapeutics, a former Bayer maker of plasma-derived protein therapies LBO'd by Cerberus, raised $950 million on Wednesday by offering 50 million shares at $19.00, at the midpoint of the $18.00 to $20.00 range. The deal was 12% larger than expected,...read more

Four IPOs scheduled for this week

Following the debut of seven IPOs last week, marking the busiest IPO week since December 2007, four additional deals are queued up for this week. Talecris Biotherapeutics (TLCR), one of the world's largest manufacturers of plasma-derived protein therapies for...read more